BACKGROUND: The health care and economic burden of @entity1211 ( @entity1211 ) has been evaluated in regard to acute @entity1211 , @entity1211 recurrence, and some @entity1211 complications, such as @entity2979 , but the cost burden attributed to bleedings is not well understood. OBJECTIVE: To evaluate health care resource utilization and costs associated with @entity548 ( @entity548 ) and clinically relevant nonmajor @entity548 (CRNMB) among a large U.S. commercially and Medicare-insured population with @entity1211 . METHODS: @entity1 (>=    18 years of age, continuously insured) with a diagnosis of @entity1211 between January 1, 2008, and December 31, 2011, were identified from the Truven Health Analytics Commercial and Medicare MarketScan databases. @entity1 who did not have any bleedings during the study period were grouped into a no-bleedings cohort and a random date after @entity1211 diagnosis was selected as the index date. @entity1211 @entity1 who experienced @entity548 within 1 year of the initial @entity1211 diagnosis were grouped into a @entity548 cohort, and @entity1 without @entity548 but with CRNMB were grouped into a CRNMB cohort. Baseline @entity1 demographics and clinical characteristics were determined for study cohorts. All-cause and @entity548 -related health care resource utilization and costs (inflation adjusted to 2013 level) during a 12-month follow-up period after the index date of the initial @entity548 event were measured and compared. Descriptive statistics were used to evaluate differences in demographics, clinical characteristics, and unadjusted health care resource utilization and costs of @entity1 cohorts. Multivariable generalized linear models were used to evaluate incremental health care costs of bleedings after adjusting for key @entity1 characteristics.    RESULTS: Among the 112,885 @entity1 identified with a @entity1211 diagnosis, 14% (n   =   15,897) had @entity548 and 14% (n   =   15,842) had CRNMB; 72% (n   =   81,146) had neither of these events occur during the study period. The mean ages of the @entity548 and CRNMB cohorts were both 63.6 years, while the mean age of the no-bleedings cohort was significantly lower at 59.6 years (P    less than    0.001). Mean Charlson Comorbidity Index scores were highest for the @entity548 cohort (3.2), followed by those of the CRNMB cohort (2.5) and the no-bleedings cohort (1.6). The @entity548 cohort had the greatest proportion of @entity1 with an initial @entity1211 event of @entity1151 only (23.5%), followed by that of the CRNMB cohort (20.2%), and the no-bleedings cohort (16.7%). For @entity548 and CRNMB cohorts, the total mean @entity548 -related inpatient and outpatient costs during the follow-up period were  49,779 (SE   =    820) and  2,187 ( 89), respectively. After adjustment for key @entity1 characteristics, the estimated mean differences in total @entity548 -related medical costs were  45,367 ( 1,853) for @entity1 with @entity548 and  2,140 ( 88) for @entity1 with CRNMB versus @entity1 with no bleedings. CONCLUSIONS: Among @entity1 with @entity1211 diagnosis in the United States, approximately 28% have a @entity548 event within 1 year of @entity1211 diagnosis, and about half of these @entity1 experience @entity548 . @entity1 with @entity548 have greatly elevated health care costs.

Incremental Health Care Burden of Bleeding Among @entity1 with XXXX in the United States.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding', 'MB', 'major bleeding'] @entity1151 :: ('MESH:D011655', 'Disease') :: ['pulmonary embolism'] @entity2979 :: ('MESH:D054070', 'Disease') :: ['postthrombotic syndrome'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['VTE', 'venous thromboembolism']
@entity1211 :: (MESH:D054556,Disease) :: ['Venous Thromboembolism']
